Galectin Therapeutics appoints Dr. Henry Brem to board of directors

GALECTIN THERAPEUTICS INC

Dr. Henry Brem appointed as independent director effective March 12, 2026.
Brem is a neurosurgeon-scientist at Johns Hopkins and former Director of Neurosurgery.
He brings expertise in translational medicine and clinical development of novel therapies.
Will receive standard non-employee director compensation per existing program.
No reportable transactions between Brem and the company under Item 404(a).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.